Axonyx Inc. Company Profile

05:15 EST 18th January 2019 | BioPortfolio

Axonyx' mission is to be the leading biopharmaceutical company that develops products and technologies to treat Alzheimer's disease (AD) and other Central Nervous System (CNS) disorders.
Axonyx' business strategy is rooted in four core areas: 1) Focused Pipeline of proprietary compounds that fulfill unmet medical needs, 2) Aggressive Growth Strategy that seeks to leverage in- and out-licensing opportunities, 3) Responsive Operational Network of dedicated high performance and experienced service providers and 4) Financial Strength allowing robust product development and pipeline growth.
Axonyx has acquired worldwide exclusive patent rights to three main classes of therapeutic compounds designed for the treatment of AD and other CNS disorders. The Company outsources principally all of its research and development activities, overseen by Company personnel and its development management group.
Axonyx is currently concentrating financial resources primarily on three compounds in development for Alzheimer's disease, including Phenserine, a symptomatic and disease progression treatment of mild to moderate AD, Posiphen™, a disease progression treatment for AD, and BisNorCymserine (BNC), a symptomatic treatment of severe AD.
As of December 31, 2004, the Company had a 34% ownership interest in OXIS International Inc., (OXIS.OB). OXIS develops, manufactures and markets selected therapeutic and diagnostic products. OXIS' research and development efforts are concentrated principally in the development of products to diagnose, treat and prevent diseases associated with free radicals and reactive oxygen species. OXIS is also a leading producer of various oxidative stress markers that can potentially be used to diagnose patients with AD, monitor therapeutic response, as well as help understand the pathophysiology of this disease process.


500 Seventh Avenue10th floor
New York
New York
United States of America


Phone: 212.645.7704
Fax: 212.989.1745

News Articles [0 Results]


Drugs and Medications [0 Results]


PubMed Articles [0 Results]


Clinical Trials [0 Results]


Companies [3 Associated Companies listed on BioPortfolio]


Axonyx is a biopharmaceutical company focused on the acquisition and development of proprietary products and technologies for the treatment and diagnosis of Alzheimer's Disease and other memory-relate...

Axonyx Inc.

Axonyx' mission is to be the leading biopharmaceutical company that develops products and technologies to treat Alzheimer's disease (AD) and other Central Nervous System (CNS) disorders. Axonyx' busin...

Axonyx Incorporated

AXYX is engaged in the business of identifying and acquiring novel post-discovery central nervous system (CNS) drug candidates to advance through clinical development towards regulatory approval an...

More Information about "Axonyx Inc." on BioPortfolio

We have published hundreds of Axonyx Inc. news stories on BioPortfolio along with dozens of Axonyx Inc. Clinical Trials and PubMed Articles about Axonyx Inc. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Axonyx Inc. Companies in our database. You can also find out about relevant Axonyx Inc. Drugs and Medications on this site too.

Quick Search


Relevant Topics

Biopharmaceuticals are medical drugs produced using biotechnology. They include proteins (including antibodies), nucleic acids (DNA, RNA or antisense oligonucleotides) and living microorganisms like virus and bacteria where the virulance of viruses and b...

Neurology - Central Nervous System (CNS)
Alzheimer's Disease Anesthesia Anxiety Disorders Autism Bipolar Disorders Dementia Epilepsy Multiple Sclerosis (MS) Neurology Pain Parkinson's Disease Sleep Disorders Neurology is the branch of me...

Corporate Database Quicklinks

Searches Linking to this Company Record